KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) EBITDA Margin: 2020-2025

Historic EBITDA Margin for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -3,327.57%.

  • Recursion Pharmaceuticals' EBITDA Margin fell 296011.00% to -3,327.57% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,656.17%, marking a year-over-year decrease of 106755.00%. This contributed to the annual value of -814.09% for FY2024, which is 2876.00% down from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' EBITDA Margin is -3,327.57%, which was down 262.97% from -916.75% recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year EBITDA Margin high stood at -367.46% for Q3 2024, and its period low was -4,042.41% during Q4 2024.
  • Its 3-year average for EBITDA Margin is -1,301.57%, with a median of -883.10% in 2023.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' EBITDA Margin surged by 2,938,181bps in 2021, and later crashed by 313,405bps in 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' EBITDA Margin (Quarterly) stood at -2,564.55% in 2021, then skyrocketed by 211,864bps to -445.91% in 2022, then crashed by 46,246bps to -908.36% in 2023, then tumbled by 313,405bps to -4,042.41% in 2024, then tumbled by 296,011bps to -3,327.57% in 2025.
  • Its EBITDA Margin was -3,327.57% in Q3 2025, compared to -916.75% in Q2 2025 and -1,297.85% in Q1 2025.